Loading...
Loading...
India's sunitinib imports from GERMANY total $43.9K across 4 shipments from 2 foreign suppliers. ILAPO leads with $32.8K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include HETERO LABS LIMITED. This corridor reflects India's pharmaceutical import demand for sunitinib โ a concentrated sourcing relationship with select suppliers from GERMANY.

ILAPO is the leading Sunitinib supplier from GERMANY to India, with import value of $32.8K across 3 shipments. The top 5 suppliers โ ILAPO, PRIVAPOSERVICES GMBH โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ILAPO | $32.8K | 3 | 74.7% |
| 2 | PRIVAPOSERVICES GMBH | $11.1K | 1 | 25.3% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | HETERO LABS LIMITED | $32.8K | 3 | 74.7% |
| 2 | SAKAR HEALTHCARE LIMITED | $11.1K | 1 | 25.3% |
GERMANY โ India trade corridor intelligence
The Germany to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year. The exchange rate between the Euro and the Indian Rupee has shown moderate fluctuations, not significantly impacting trade volumes.
The Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially reducing reliance on imports of finished pharmaceutical formulations. However, the immediate impact on Sunitinib imports is limited due to the specialized nature of the product and the time required to establish domestic production capabilities. Import substitution policies are being evaluated, but no significant changes have been implemented as of now.
India and Germany maintain strong trade relations, with ongoing discussions to enhance pharmaceutical trade. Negotiations for Free Trade Agreements (FTAs) are in progress, aiming to reduce trade barriers and facilitate smoother transactions. Mutual recognition of Good Manufacturing Practices (GMP) is being considered to streamline regulatory processes. These efforts are expected to positively impact pharmaceutical trade between the two nations.
The landed cost of importing Sunitinib formulations from Germany to India includes the following components:
Per-unit estimates depend on the total quantity imported.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Sunitinib into India, the foreign manufacturer must obtain a Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months. Sunitinib formulations under HS Code 30049099 are subject to these regulatory requirements to ensure quality, safety, and efficacy.
Imported Sunitinib formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate product stability in India's climate. Port inspections by customs drug inspectors are conducted to verify compliance with these standards. Failure to meet quality standards can result in rejection of the batch and potential penalties.
Between 2024 and 2026, CDSCO has implemented stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing. The Production-Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, but compliance with updated regulatory requirements remains essential.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Sunitinib formulations primarily due to the unavailability of certain patented or specialized dosage forms domestically. The market size for Sunitinib in India is substantial, with a growing number of patients requiring treatment for various cancers. Domestic manufacturers may lack the capacity or technology to produce specific Sunitinib formulations, leading to reliance on imports to meet patient needs.
The Basic Customs Duty (BCD) for Sunitinib formulations under HS Code 30049099 is 10%. A Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which can vary. There are no specific exemptions or preferential duty rates for imports from Germany. The total landed duty percentage depends on the CIF value and applicable IGST rates.
India sources Sunitinib formulations from Germany due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Germany's share in India's Sunitinib import market is significant, with other suppliers like China, the US, and domestic manufacturers also contributing to the market. Germany's competitive advantage lies in its established reputation for quality and innovation in pharmaceutical products.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Sunitinib formulations from Germany due to the availability of patented formulations and specialized dosage forms not produced domestically. Germany's advanced pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred source. Specific formulations, such as certain extended-release tablets, are not manufactured in India, necessitating imports to meet patient needs.
Compared to other sources like China, the EU, and the US, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While China may offer lower prices, concerns about quality and regulatory standards make Germany a more reliable choice. The US provides high-quality products but at higher costs, making Germany a balanced option.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it's prudent to monitor the supply chain regularly. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Sunitinib suppliers from GERMANY to India include ILAPO, PRIVAPOSERVICES GMBH. The leading supplier is ILAPO with import value of $32.8K USD across 3 shipments. India imported Sunitinib worth $43.9K USD from GERMANY in total across 4 shipments.
India imported Sunitinib worth $43.9K USD from GERMANY across 4 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Sunitinib sourced from GERMANY include HETERO LABS LIMITED, SAKAR HEALTHCARE LIMITED. The largest buyer is HETERO LABS LIMITED with $32.8K in imports across 3 shipments.
The total value of Sunitinib imports from GERMANY to India is $43.9K USD, across 4 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4 Verified Shipments
2 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists